Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Clairvoyant begins Phase 2 psilocybin study for alcohol use disorder

By Brian Buntz | July 7, 2022

Clairvoyant TherapeuticsClairvoyant Therapeutics, a Canadian drug developer, has initiated the first of 15 planned sites for the Phase 2 CLARITY clinical study investigating the use of magic mushroom molecule psilocybin to treat alcohol use disorder (AUD).

The randomized, placebo-controlled study will evaluate the safety and efficacy of 25 mg of synthetic psilocybin with Motivational Enhancement Therapy (MET), a counseling method designed to elicit an internally motivated behavior change regarding substance abuse.

The CLARITY trial has won regulatory approval. Clairvoyant is currently working on obtaining regulatory approval to expand the trial to a number of EU countries.

Edmonton, Alberta-based Clairvoyant Therapeutics aims to win regulatory approval for psilocybin therapy in the EU, UK and Canada by 2026.

The CLARITY trial provides “a great opportunity to advance the science on psilocybin than has historically been done,” said Greg Engel, Clairvoyant Therapeutics’ director, in a January podcast.

Researchers first tested psychedelics psilocybin and LSD to treat AUD in the 1950s and 1960s.

In recent years, psilocybin, in particular, has emerged as a potential treatment for mental health disorders, including AUD.

The trend has elicited mixed reactions from psychiatrists. A trio of skeptical psychiatrists observed in JAMA Psychiatry in 2021 that there was little psychedelic research supported by federal agencies such as the National Institutes of Mental Health (NIMH) or major pharmaceutical or biotech companies. They also observed that the tendency of many psychedelic companies to develop patented proprietary versions of psychedelic compounds could limit the generalizability of clinical outcomes.


Filed Under: clinical trials, Drug Discovery, Psychiatric/psychotropic drugs
Tagged With: Clairvoyant Therapeutics, psilocybin
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
How biosimulation and virtual trials can bust through clinical trial roadblocks
Complexity’s counterpoint: Understanding protocol optimization 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE